Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, ...

Novavax (NVAX) closed the most recent trading day at $6.39, moving -0.31% from the previous trading session. This move lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a drop ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a ...

Shares of Novavax Inc. NVAX shed 3.23% to $6.00 Thursday, on what proved to be an all-around dismal trading session for the ...

According to TipRanks, Stranahan is an analyst with an average return of -15.0% and a 32.39% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Candel Therapeutics, ...

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Shares of Novavax, Inc. (NASDAQ:NVAX – Get Free Report) have received an average recommendation of “Hold” from the seven ...

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

Novavax (NVAX) announced preliminary results from the SHIELD-Utah study that showed Novavax’s COVID-19 Vaccine, Adjuvanted 2024-2025 Formula ...

Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary ...